UY35036A - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents
Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10aInfo
- Publication number
- UY35036A UY35036A UY0001035036A UY35036A UY35036A UY 35036 A UY35036 A UY 35036A UY 0001035036 A UY0001035036 A UY 0001035036A UY 35036 A UY35036 A UY 35036A UY 35036 A UY35036 A UY 35036A
- Authority
- UY
- Uruguay
- Prior art keywords
- phosphodiesterase
- type
- inhibiting compounds
- new
- new inhibiting
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702005P | 2012-09-17 | 2012-09-17 | |
| US201261702371P | 2012-09-18 | 2012-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35036A true UY35036A (es) | 2014-03-31 |
Family
ID=49226152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035036A UY35036A (es) | 2012-09-17 | 2013-09-17 | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9388180B2 (enExample) |
| EP (1) | EP2895489B1 (enExample) |
| JP (1) | JP2015528484A (enExample) |
| KR (1) | KR20150056844A (enExample) |
| CN (1) | CN105102461A (enExample) |
| AR (1) | AR092595A1 (enExample) |
| AU (1) | AU2013314244A1 (enExample) |
| BR (1) | BR112015005935A2 (enExample) |
| CA (1) | CA2883910A1 (enExample) |
| HK (1) | HK1206728A1 (enExample) |
| IL (1) | IL237626A0 (enExample) |
| IN (1) | IN2015DN01900A (enExample) |
| MX (1) | MX2015003419A (enExample) |
| RU (1) | RU2015114331A (enExample) |
| SG (1) | SG11201502074YA (enExample) |
| TW (1) | TW201418264A (enExample) |
| UY (1) | UY35036A (enExample) |
| WO (1) | WO2014041175A1 (enExample) |
| ZA (1) | ZA201501458B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015535227A (ja) | 2012-10-26 | 2015-12-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｓｙｋの３，４−二置換１ｈ−ピラゾール及び４，５−二置換チアゾール阻害剤 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN111592495A (zh) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US7057042B2 (en) * | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| WO2005120514A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| AU2005282721A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| AP2007003923A0 (en) * | 2004-09-30 | 2007-02-28 | Tibotec Pharm Ltd | Hcv inhibiting bi-cyclic pyrimidines |
| JP2009504759A (ja) | 2005-08-16 | 2009-02-05 | メモリ ファーマセチカル コーポレーション | ホスホジエステラーゼ１０阻害剤 |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| CA2635439A1 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| EP1991540A1 (en) | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| US20070265256A1 (en) | 2006-02-21 | 2007-11-15 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| JP2009527542A (ja) | 2006-02-23 | 2009-07-30 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害薬としての置換キナゾリン |
| JP2009528365A (ja) | 2006-02-28 | 2009-08-06 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体 |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| MX2008011257A (es) | 2006-03-08 | 2008-09-25 | Amgen Inc | Derivados de quinolina e isoquinolina como inhibidores de fosfodiesterasa 10. |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| EP2057153B1 (en) | 2006-07-10 | 2012-09-12 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| WO2009070583A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| US7875618B2 (en) * | 2007-11-30 | 2011-01-25 | Wyeth | Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders |
| CA2706986A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| RS54560B1 (sr) | 2008-06-10 | 2016-06-30 | Abbvie Inc. | Triciklična jedinjenja |
| US20100120763A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
| US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
-
2013
- 2013-09-16 RU RU2015114331A patent/RU2015114331A/ru not_active Application Discontinuation
- 2013-09-16 JP JP2015531593A patent/JP2015528484A/ja not_active Withdrawn
- 2013-09-16 WO PCT/EP2013/069173 patent/WO2014041175A1/en not_active Ceased
- 2013-09-16 EP EP13765695.5A patent/EP2895489B1/en not_active Not-in-force
- 2013-09-16 SG SG11201502074YA patent/SG11201502074YA/en unknown
- 2013-09-16 KR KR1020157009897A patent/KR20150056844A/ko not_active Withdrawn
- 2013-09-16 AU AU2013314244A patent/AU2013314244A1/en not_active Abandoned
- 2013-09-16 HK HK15107215.7A patent/HK1206728A1/xx unknown
- 2013-09-16 IN IN1900DEN2015 patent/IN2015DN01900A/en unknown
- 2013-09-16 CA CA2883910A patent/CA2883910A1/en not_active Abandoned
- 2013-09-16 CN CN201380048224.3A patent/CN105102461A/zh active Pending
- 2013-09-16 MX MX2015003419A patent/MX2015003419A/es unknown
- 2013-09-16 BR BR112015005935A patent/BR112015005935A2/pt not_active IP Right Cessation
- 2013-09-17 US US14/029,142 patent/US9388180B2/en not_active Expired - Fee Related
- 2013-09-17 TW TW102133710A patent/TW201418264A/zh unknown
- 2013-09-17 UY UY0001035036A patent/UY35036A/es not_active Application Discontinuation
- 2013-09-17 AR ARP130103326A patent/AR092595A1/es unknown
-
2015
- 2015-03-03 ZA ZA2015/01458A patent/ZA201501458B/en unknown
- 2015-03-09 IL IL237626A patent/IL237626A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013314244A8 (en) | 2015-04-30 |
| US20140107126A1 (en) | 2014-04-17 |
| WO2014041175A1 (en) | 2014-03-20 |
| US9388180B2 (en) | 2016-07-12 |
| KR20150056844A (ko) | 2015-05-27 |
| EP2895489B1 (en) | 2017-10-18 |
| AU2013314244A1 (en) | 2015-03-12 |
| CN105102461A (zh) | 2015-11-25 |
| ZA201501458B (en) | 2018-11-28 |
| EP2895489A1 (en) | 2015-07-22 |
| HK1206728A1 (en) | 2016-01-15 |
| CA2883910A1 (en) | 2014-03-20 |
| IN2015DN01900A (enExample) | 2015-08-07 |
| RU2015114331A (ru) | 2016-11-10 |
| MX2015003419A (es) | 2015-09-23 |
| AR092595A1 (es) | 2015-04-29 |
| JP2015528484A (ja) | 2015-09-28 |
| TW201418264A (zh) | 2014-05-16 |
| SG11201502074YA (en) | 2015-05-28 |
| IL237626A0 (en) | 2015-04-30 |
| BR112015005935A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000251A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| BR112015020795A2 (pt) | derivados de pirazol novos | |
| CR20120277A (es) | Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
| MX378288B (es) | Inhibidores de pirimidina del fgfr4. | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| UA116395C2 (uk) | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ | |
| BR112015009600A2 (pt) | piridina-2-amidas úteis como agonistas cb2 | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| CO6741154A2 (es) | Compuestos de triazolopiridina | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| UA107671C2 (en) | N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives | |
| BR112018011562A2 (pt) | novos derivados de fenil | |
| UA106889C2 (uk) | Похідні n1-ацил-5-фторпіримідинону | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| UY35036A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| AR091888A1 (es) | Compuestos de urea y su uso como inhibidores de enzimas | |
| BR112014019220A8 (pt) | Novos derivados de pirrolidina | |
| BR112015030824A2 (pt) | novos derivados de tetrazolona | |
| CO2018007756A2 (es) | Nuevos derivados pirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20210617 |